Articles tagged with Lung Cancer
A 50-gene predictor has been found to accurately identify patients with low risk of relapse after surgery. The gene signature is related to the activity of B lymphocytes and suggests an enhanced immune response against the tumor.
Researchers present new methods for early lung cancer detection, including digital chest tomography and a blood test for BARD1 antibodies. These techniques have shown promising results in detecting lung cancer with high sensitivity and specificity.
A new analysis of the TORCH trial found that erlotinib is most effective in patients with EGFR mutations, while those with wild-type tumors should receive standard chemotherapy first. The study confirms the importance of biomarker testing to guide treatment decisions.
Researchers have identified potential biomarkers for personalized medicine in lung cancer, such as a test that predicts patient response to certain treatments. The findings suggest that these innovative approaches could lead to more effective treatment strategies for patients with lung cancer.
Researchers analyzed data from 4,168 Medicare beneficiaries with advanced non-small cell lung cancer aged 65 or older. They found no significant difference in overall survival between those treated with bevacizumab and those receiving standard chemotherapy alone. The study's findings suggest that bevacizumab should not be considered th...
A study by Dana-Farber Cancer Institute researchers found that adding bevacizumab to standard chemotherapy for non-small cell lung cancer in patients over 65 did not significantly increase survival rates. The treatment approach was previously approved by the FDA but failed to show substantial benefits.
A recent study published in the Journal of Thoracic Oncology reveals that Japanese patients with lung cancer are more likely to harbor specific genetic mutations and have a different risk profile compared to Western patients. The research highlights the importance of considering genetic factors in lung cancer diagnosis and treatment.
Researchers analyzed four studies and found that regular follow-up reduces crisis-driven health episodes. While no preferred method was determined, the authors recommend guidelines for initial specialist appointments and protocol-driven follow-up led by a lung cancer clinical nurse specialist.
Researchers found that fine needle aspiration is highly sensitive for diagnosing lung cancer, but has a high rate of false negatives, especially in larger lesions. The study recommends repeat imaging to monitor for growth and suggests this method can help patients avoid unnecessary surgery.
Three noteworthy studies were presented, including a study on KRAS in non-small cell lung cancer patients and another on dacomitinib's favorable clinical benefits. Additionally, researchers validated the role of tumor lymphocytic infiltration as a favorable prognostic factor for resectable non-small cell lung cancer.
A new study by Rush University Medical Center found that lung cancer screening with low-dose spiral CT scans can detect early-stage disease and reduce cancer-related deaths. The study estimates that commercial insurers should consider providing this benefit to high-risk individuals, which could lead to significant cost savings.
A University of Colorado Cancer Center study found that men taking crizotinib for lung cancer experience a significant drop in testosterone levels, which can lead to fatigue, low bone density, and decreased sex drive. Regular monitoring and treatment of testosterone deficiency can improve patients' overall quality of life.
A phase II clinical trial showed encouraging survival in patients with stage 3B/4 non-small cell lung cancer (NSCLC) treated with belagenpumatucel-L. The median survival rate was 14.5 months, and the five-year survival rate was 20%. Patients with stable disease had a longer median survival of 44 months.
Scientists at Fox Chase Cancer Center discovered a link between estrogen and tobacco smoke, suggesting that new therapies targeting estrogen metabolism may help prevent or treat lung cancer. Estrogen metabolites increase in the lungs of mice exposed to tobacco smoke, promoting cell growth and damage.
Researchers at Moffitt Cancer Center found that 38% of lung cancer patients suffer from depression, with greater stigma levels related to higher depressive symptoms. Psychotherapeutic approaches may help alleviate or prevent depression by altering perceptions of stigma.
Researchers found that adding RNAi to standard TKI or antibody therapy can enhance the effect of therapy on NSCLC cell death and slow cell growth. The treatment may benefit patients with EGFR mutations who do not respond to TKI, or those whose cancer is driven by overactive EGFR production.
Research reveals that BRG1 gene mutations render tumor cells unresponsive to hormones like retinoic acid and steroids, leading to continued growth and spreading.
A panel of 10 serum protein biomarkers shows promise in predicting lung cancer risk and aiding early detection. Research suggests that these biomarkers could reduce the number of unnecessary lung biopsies needed, offering a more targeted approach to diagnosis.
A recent study published in Journal of Thoracic Oncology suggests that CYFRA21-1 levels can reliably indicate patient response to chemotherapy for non-small cell lung cancer (NSCLC). Higher baseline concentrations were linked to poorer overall and failure-free survival. Further research is needed to confirm these findings.
A recent study published in the Journal of Thoracic Oncology suggests that pleurectomy/decortication (P/D) is a superior approach to extrapleural pnemonectomy (EPP) for patients with early-stage malignant pleural mesothelioma. P/D resulted in significantly better survival rates and lower mortality and morbidity compared to EPP.
An NIH study found that tobacco control programs and policies have prevented over 795,000 lung cancer deaths in the US from 1975 through 2000. Further reductions are possible with continued and enhanced efforts.
A study led by Fred Hutchinson Cancer Research Center found that US tobacco-control efforts significantly reduced lung cancer deaths between 1975 and 2000. The researchers estimated that if all smokers had quit after the 1964 Surgeon General's report, an additional 2.5 million people would not have died from lung cancer.
Between 1975-2000, US lung cancer mortality declined significantly due to reduced smoking rates. Tobacco control measures such as increased taxes and smoke-free laws contributed to this decrease.
Researchers identified ways to reduce costs of molecular profiling and targeted therapies, enabling more patients to benefit from personalized treatments. The methods include recommending testing only for high-risk patients and merging tests to lower combined prices.
A cohort study and nested case-control study found a statistically significantly increased risk of lung cancer with increasing diesel exhaust exposure among workers and urban populations. Studies suggest stringent occupational and environmental standards are necessary to reduce the health burden of carcinogenic diesel exhaust.
New research highlights the importance of nurses in alleviating concerns and existential issues in newly diagnosed lung cancer patients. Nurses can provide supportive care, address death-related concerns, and help patients locate resources to manage end-of-life affairs.
Breast cancer death rates are declining across the EU, with a predicted drop of 9% for women and 13% among young women. Pancreatic cancer deaths are rising, but overall cancer mortality rates are falling due to advancements in treatment and prevention.
Researchers discovered that manipulating two biochemical signals regulating mitochondria in cells can shrink human lung cancers in mice. By boosting fusion signal or blocking fission, they reduced cell division and increased cell death.
Lung cancer patients face geographic challenges to access clinical trials due to molecular preselection. Researchers propose using online patient communities and innovative trial approaches to inform patients about trials, accelerate research, and address practical challenges in conducting personalized medicine trials.
A new study published in CANCER found that many older lung cancer patients receive radiation therapy without extending their lifespan. Researchers analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to determine if additional radiation therapy after surgery improves survival rates.
Researchers from Mount Sinai School of Medicine found that post-operative radiation therapy does not prolong life in older adults with locally advanced non-small cell lung cancer. The study analyzed data from over 1,300 patients and found no significant improvement in one-year or three-year survival rates.
IKBKE is induced by tobacco carcinogens and mediates tobacco action in promoting lung cancer cell survival. Knocking down IKBKE sensitizes cells to chemotherapy, suggesting a therapeutic role for targeting this pathway.
Researchers developed a highly sensitive blood test for detecting and analyzing circulating tumor cells (CTCs) in cancer patients. The 'biopsy in a blood test' provides information comparable to surgical biopsies, enabling better monitoring, prediction, and understanding of cancer progression.
Different subgroups of non-small cell lung cancer exhibit distinct patterns of spread in the body, suggesting fundamentally different diseases. Targeted therapies have shown dramatic clinical responses in patients with ALK positive NSCLC, offering new hope for treatment.
A recent study found that the STAT3 gene is activated in some non-small cell lung cancer cell lines by the JAK2 protein, which may not be effectively inhibited by drugs targeting specific mutations. This suggests a potential role for combination therapy to combat NSCLC driven by STAT3-JAK2 signaling.
Researchers at Massachusetts General Hospital have defined a new genetic subtype of lung cancer driven by ROS1 gene rearrangements. Crizotinib treatment has shown promising results in controlling tumors in patients with this subtype, offering a new therapeutic option.
A new lung cancer assay measures gene activity in tumor tissue and provides a risk score to predict patient survival after surgery. The assay has been validated in two independent trials and shows promise in identifying patients at highest risk of mortality.
A new molecular test can predict the likelihood of death from early-stage lung cancer with greater accuracy than traditional methods. The test, which measures gene activity in cancerous tissue, has been shown to improve prognosis and guide treatment decisions for patients with non-squamous non-small cell lung cancer.
A new study found that many cancer patients continue to smoke after diagnosis, with 39% of lung cancer and 14% of colorectal cancer patients smoking at diagnosis. Factors such as insurance, emotional support, and education level can predict continued smoking in these patients.
Researchers found that MET gene overexpression leads to deregulation of microRNAs, causing gefitinib resistance in lung cancer. Combining targeted drugs with microRNA blockers may improve treatment efficacy.
Researchers decoded the behavior of lysozymes, a protein in teardrops that chomps through bacterial cell walls. The discovery could lead to early detection and treatment of cancers.
Scientists have documented how ALK positive advanced non-small cell lung cancer becomes resistant to crizotinib, a previously effective treatment. Researchers now aim to develop combination therapies to tackle this resistance and improve patient outcomes.
Research finds a significant association between pulmonary TB and EGFR mutations in lung cancer patients. The study reveals that tumors with these mutations respond well to targeted therapies, offering new hope for treatment.
Researchers found significant cancer-like gene expression changes in healthy smokers' large airway epithelia compared to nonsmokers. The study suggests smoking induces molecular alterations in the large airway epithelium prior to disease development, making it a primary site for lung cancer risk.
In a preclinical study, ganetespib slowed the growth of cancer cells from non-small cell lung tumors with a KRAS gene mutation. The drug was more active when combined with traditional lung cancer treatments and other targeted therapies, indicating its potential effectiveness in treating patients with KRAS-mutant NSCLC.
Researchers developed a sensitive test to analyze circulating tumor cells in blood, enabling clinicians to track cancer progress and treatments. The method uses high-throughput mass spectrometry analysis, allowing for the detection of genetic mutations present in small numbers of malignant cells.
TGen researchers identify multiple novel mutations and pathway changes in never-smoker lung cancer patients, diverging from those found in smokers. These findings hold promise for developing therapeutic targets in this patient population.
Researchers identified potential gene mutations and pathway alterations that could lead to lung cancer in never-smokers. They found that these patients' tumors lacked common genes associated with lung cancer, making them ideal cases for discovering new mutations that may drive the disease.
Researchers found sorafenib to be effective in patients with non-small cell lung cancer and a KRAS mutation, achieving a 52.6% rate of no progression at six weeks. However, median overall survival was only 5.3 months, indicating unsatisfactory outcomes.
A preclinical study found that a combination of estrogen-targeting drugs significantly reduced tobacco carcinogen-induced lung tumors in mice. The treatment, which blocks estrogen production and its effects on the body, showed maximum antitumor effects in both healthy and precancerous cells.
Research finds that multicentric lung adenocarcinoma often shares the same genetic mutation, indicating a possible common origin for these tumors. The study identified genetically distinct molecular subsets using EGFR and KRAS genes.
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The signature was able to distinguish between low and high malignancy risk groups, correlating with good or poor overall survival rates.
Researchers have identified a previously unknown gene fusion event in lung adenocarcinoma cases in never-smokers, suggesting that this fusion could serve as a therapeutic target. The study found the KIF5B-RET fusion to occur in about 6% of all lung adenocarcinoma cases.
A Wayne State University study shows that soybean compounds can make radiation treatment of lung cancer more effective while helping to preserve normal tissue. The compounds, known as isoflavones, block DNA repair mechanisms and molecular survival pathways in cancer cells, making them more vulnerable to ionizing radiation.
The IASLC has set up a Strategic CT Screening Advisory Committee to define optimal approaches to lung cancer screening. The committee will focus on six key components, including identifying high-risk individuals and developing radiological guidelines for national screening programs.
Researchers identified STARD9, a kinesin-like protein involved in cell division, as a potential target for cancer therapy. Depleting STARD9 stops cancer cells from dividing and causes them to die quickly, showing promise in treating certain types of melanoma and non-small cell lung cancers.
Researchers found a strong association between smoking and squamous cell carcinoma in women, with increased risk seen with higher cigarette consumption. Smoking history was more strongly linked to SCC in women than men, with a four-fold increase in those who had smoked for 20 years or more.
Researchers found that silibinin from milk thistle prevents lung cancer growth by inhibiting COX2 and iNOS production. This natural compound may be as effective as current treatments for lung cancer, targeting promising therapeutic targets STAT1 and STAT3.
Researchers found that COPD patients are 5 times more likely to develop lung cancer than normal smokers. Early detection of COPD through lung function testing can help identify high-risk patients for lung cancer screening.
A combination epigenetic therapy has shown positive effects in a small clinical trial of late-stage lung cancer patients. The treatment increased median survival by two months and showed complete or near-complete responses in some patients. Researchers believe the therapy may reprogram gene expression to prevent cancer growth.